Bone health is a crucial factor to assure quality of life

A novel review of Tilman Rachner describes how adjuvant endocrine therapies of breast and prostate cancer impair bone health to reduce risk of fracture. Preservation of bone health still remains a long-term clinical challenge in patients with breast and prostate cancer. Dr. Rachner emphasizes: “Each patient receiving endocrine therapy should be stringently assessed for their individual fracture risk when therapy is initiated, and this risk should be reassessed in adequate intervals or whenever major changes to disease status or treatment occur.”